Flag of the European Union EU Clinical Trials Register Help

Clinical trials for First impression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    352 result(s) found for: First impression. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-003851-41 Sponsor Protocol Number: Bumetanide/Autism Start Date*: 2021-11-08
    Sponsor Name:Gillberg Neuropsychiatry Centre
    Full Title: A Randomized Waitlist-Control Trial with Bumetanide in Children with Autism
    Medical condition: Autism spectrum disorder, a neurodevelopmental disorder with onset in childhood. The disorder implies deficits in social and communicative abilities and restricted interests and behaviors. Many chi...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004331-71 Sponsor Protocol Number: IB1001-201 Start Date*: 2019-05-08
    Sponsor Name:IntraBio Ltd
    Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study
    Medical condition: Niemann-Pick Disease type C (NPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004406-25 Sponsor Protocol Number: IB1001-202 Start Date*: 2019-05-09
    Sponsor Name:IntraBio Ltd
    Full Title: Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multicenter, open-label, rater-blinded Phase II study.
    Medical condition: GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-000382-41 Sponsor Protocol Number: WA29330 Start Date*: 2015-03-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris
    Medical condition: Pemphigus Vulgaris (PV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001221-16 Sponsor Protocol Number: RISSCH3024 Start Date*: 2015-03-31
    Sponsor Name:Janssen Cilag N.V./S.A
    Full Title: A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000415-25 Sponsor Protocol Number: NAS-S-01 Start Date*: 2013-11-07
    Sponsor Name:Clinirx Tangent Research
    Full Title: A randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Naproxen, Simvastatin and their combination, compared to placebo as add-on to anti-psychotics in the trea...
    Medical condition: schizophrenia and schizoaffective disorder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005138-21 Sponsor Protocol Number: TC-5619-23-CRD-003 Start Date*: 2012-04-03
    Sponsor Name:Targacept Inc.
    Full Title: A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in ou...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020912-12 Sponsor Protocol Number: VP-VEC-162-3202 Start Date*: 2010-08-26
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: Open-label safety study of a 1-year 20 mg dose regimen of tasimelteon for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in blind individuals with no light perception.
    Medical condition: Non-24 Hour Sleep-Wake Disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10013419 Disruptions of 24 hour sleep-wake cycle LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004117-33 Sponsor Protocol Number: H3B109689 Start Date*: 2007-12-17
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selec...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-003141-11 Sponsor Protocol Number: NBI-827104-CSWS2010 Start Date*: 2021-09-03
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with E...
    Medical condition: Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep (EECSWS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002163-17 Sponsor Protocol Number: 15-138 Start Date*: 2018-10-25
    Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A)
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.
    Medical condition: Friedreich Ataxia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000358-23 Sponsor Protocol Number: CMS-001 Start Date*: 2019-02-06
    Sponsor Name:CATALYST PHARMACEUTICALS INC.
    Full Title: A phase 3, multicenter, double-blind, placebo-controlled, randomized, outpatient two-period two-treatment crossover study to evaluate the efficacy and safety of amifampridine phosphate (3,4 diamino...
    Medical condition: Congenital myasthenic syndromes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028424 Myasthenic syndrome PT
    20.0 10029205 - Nervous system disorders 10028425 Myasthenic syndromes in diseases classified elsewhere LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001581-42 Sponsor Protocol Number: 17972A Start Date*: 2018-11-19
    Sponsor Name:H. Lunbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with sc...
    Medical condition: schizophrenia with persistent prominent negative symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022744-21 Sponsor Protocol Number: AB08003 Start Date*: 2013-06-05
    Sponsor Name:AB Science
    Full Title: A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepr...
    Medical condition: mood disorders associated to major depression or dysthymic disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 10037175 - Psychiatric disorders 10013982 Dysthymic disorder PT
    16.0 10037175 - Psychiatric disorders 10012374 Depressed mood PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000808-22 Sponsor Protocol Number: 000278 Start Date*: 2017-11-13
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-label Trial Investigating the Association Between Nocturia and Sleep During 12 Weeks of Treatment with Desmopressin Orally Disintegrating Tablet (ODT) for Nocturia due to Nocturnal Polyuria...
    Medical condition: Nocturia due to Nocturnal Polyuria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017861 10064016 Nocturnal polyuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000001-23 Sponsor Protocol Number: DroSpas-1 Start Date*: 2018-10-25
    Sponsor Name:Bionorica SE
    Full Title: A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in pat...
    Medical condition: Symptomatic relief of spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001153-10 Sponsor Protocol Number: X4P-001-103 Start Date*: 2020-02-05
    Sponsor Name:X4 Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
    Medical condition: WHIM Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010512 Congenital immunodeficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) ES (Ongoing) PL (Completed) AT (Completed) DE (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001347-31 Sponsor Protocol Number: M13-954 Start Date*: 2013-11-12
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects with Diabetes Mellitus type 2
    Medical condition: Pancreatic exocrine insufficiency in diabetes type II
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000832-23 Sponsor Protocol Number: KH176-203 Start Date*: 2021-07-12
    Sponsor Name:Khondrion B.V.
    Full Title: A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutatio...
    Medical condition: A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) tRNALeu(UUR) m.3243A>G mutation (including but not limited to MELAS. MIDD and mixed phenotypes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003024-16 Sponsor Protocol Number: ACT16482 Start Date*: 2021-06-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol
    Medical condition: Plasma cell myeloma refractory
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081847 Plasma cell myeloma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FR (Completed) GR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 12:59:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA